Baird Maintains an 'Outperform' on Achillion Pharmaceuticals (ACHN); Reassuring Clarification on '1625

Baird maintains an 'Outperform' on Achillion Pharmaceuticals (NASDAQ: ACHN).

Analyst, Thomas Russo, said, "Incrementally positive following clarification of 4/21 update and conversation with management. We came away from EASL continuing to believe ACHN-8217's assets could remain relevant in HCV with success and, while certainly something to monitor, were not as surprised as maybe some others on safety/tolerability. Our concern had been whether there might be an emerging fundamental question on efficacy, but after the clarifying update we are reassured there. Management corrected its original sub-optimal handling of this, and the thesis is reinforced."

For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $8.28 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential